nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Vismodegib—skin cancer	0.128	0.249	CbGbCtD
Paroxetine—CYP2C9—Vismodegib—skin cancer	0.0891	0.173	CbGbCtD
Paroxetine—ABCB1—Vismodegib—skin cancer	0.0864	0.168	CbGbCtD
Paroxetine—CYP2D6—Vemurafenib—skin cancer	0.0644	0.125	CbGbCtD
Paroxetine—ABCB1—Dactinomycin—skin cancer	0.0454	0.0884	CbGbCtD
Paroxetine—CYP2C8—Fluorouracil—skin cancer	0.0454	0.0883	CbGbCtD
Paroxetine—CYP2C9—Fluorouracil—skin cancer	0.0316	0.0616	CbGbCtD
Paroxetine—ABCB1—Docetaxel—skin cancer	0.0234	0.0457	CbGbCtD
Paroxetine—CHRM3—muscle of abdomen—skin cancer	0.01	0.129	CbGeAlD
Paroxetine—TACR1—nerve—skin cancer	0.00758	0.0978	CbGeAlD
Paroxetine—CHRM5—skin epidermis—skin cancer	0.00654	0.0843	CbGeAlD
Paroxetine—SLC6A3—nerve—skin cancer	0.00381	0.0492	CbGeAlD
Paroxetine—SLC6A2—nerve—skin cancer	0.00308	0.0397	CbGeAlD
Paroxetine—TACR1—connective tissue—skin cancer	0.00305	0.0394	CbGeAlD
Paroxetine—HTR2A—hindlimb—skin cancer	0.00304	0.0392	CbGeAlD
Paroxetine—HTR2A—appendage—skin cancer	0.00261	0.0336	CbGeAlD
Paroxetine—TACR1—female reproductive system—skin cancer	0.00215	0.0278	CbGeAlD
Paroxetine—CHRM5—epithelium—skin cancer	0.00213	0.0275	CbGeAlD
Paroxetine—CHRM5—skin of body—skin cancer	0.00203	0.0261	CbGeAlD
Paroxetine—HTR2A—nerve—skin cancer	0.00185	0.0239	CbGeAlD
Paroxetine—TACR1—head—skin cancer	0.0018	0.0232	CbGeAlD
Paroxetine—CHRM4—head—skin cancer	0.00169	0.0218	CbGeAlD
Paroxetine—HTR2A—endothelium—skin cancer	0.00157	0.0203	CbGeAlD
Paroxetine—HTR2A—blood vessel—skin cancer	0.00145	0.0187	CbGeAlD
Paroxetine—CHRM5—head—skin cancer	0.00132	0.017	CbGeAlD
Paroxetine—TACR1—lymph node—skin cancer	0.00126	0.0162	CbGeAlD
Paroxetine—HTR2A—neck—skin cancer	0.00104	0.0134	CbGeAlD
Paroxetine—SLC6A4—female reproductive system—skin cancer	0.000992	0.0128	CbGeAlD
Paroxetine—CHRM1—female reproductive system—skin cancer	0.000988	0.0128	CbGeAlD
Paroxetine—ABCB1—blood vessel—skin cancer	0.000952	0.0123	CbGeAlD
Paroxetine—CHRM2—head—skin cancer	0.000907	0.0117	CbGeAlD
Paroxetine—SLC6A3—head—skin cancer	0.000905	0.0117	CbGeAlD
Paroxetine—CHRM3—female reproductive system—skin cancer	0.000885	0.0114	CbGeAlD
Paroxetine—SLC6A2—female reproductive system—skin cancer	0.000874	0.0113	CbGeAlD
Paroxetine—SLC6A4—head—skin cancer	0.000829	0.0107	CbGeAlD
Paroxetine—CHRM1—head—skin cancer	0.000826	0.0107	CbGeAlD
Paroxetine—CYP2B6—skin of body—skin cancer	0.000824	0.0106	CbGeAlD
Paroxetine—HTR2A—connective tissue—skin cancer	0.000744	0.0096	CbGeAlD
Paroxetine—CHRM3—head—skin cancer	0.000739	0.00953	CbGeAlD
Paroxetine—SLC6A2—head—skin cancer	0.00073	0.00941	CbGeAlD
Paroxetine—CYP2C8—female reproductive system—skin cancer	0.000718	0.00926	CbGeAlD
Paroxetine—HTR2A—epithelium—skin cancer	0.000707	0.00912	CbGeAlD
Paroxetine—CYP2B6—lymphoid tissue—skin cancer	0.000667	0.00861	CbGeAlD
Paroxetine—CYP2B6—female reproductive system—skin cancer	0.000644	0.0083	CbGeAlD
Paroxetine—CYP2C9—female reproductive system—skin cancer	0.000637	0.00822	CbGeAlD
Paroxetine—CYP2B6—head—skin cancer	0.000538	0.00694	CbGeAlD
Paroxetine—HTR2A—female reproductive system—skin cancer	0.000525	0.00677	CbGeAlD
Paroxetine—SLC6A2—lymph node—skin cancer	0.000511	0.00659	CbGeAlD
Paroxetine—CYP2D6—female reproductive system—skin cancer	0.000478	0.00617	CbGeAlD
Paroxetine—ABCB1—epithelium—skin cancer	0.000463	0.00597	CbGeAlD
Paroxetine—HTR2A—head—skin cancer	0.000439	0.00566	CbGeAlD
Paroxetine—ABCB1—mammalian vulva—skin cancer	0.000402	0.00518	CbGeAlD
Paroxetine—CYP2D6—head—skin cancer	0.0004	0.00515	CbGeAlD
Paroxetine—ABCB1—lymphoid tissue—skin cancer	0.000357	0.0046	CbGeAlD
Paroxetine—ABCB1—female reproductive system—skin cancer	0.000344	0.00444	CbGeAlD
Paroxetine—Orthostatic hypotension—Docetaxel—skin cancer	0.000288	0.000723	CcSEcCtD
Paroxetine—Rash—Vemurafenib—skin cancer	0.000288	0.000722	CcSEcCtD
Paroxetine—Mental disorder—Temozolomide—skin cancer	0.000288	0.000722	CcSEcCtD
Paroxetine—Dermatitis—Vemurafenib—skin cancer	0.000288	0.000721	CcSEcCtD
Paroxetine—ABCB1—head—skin cancer	0.000287	0.00371	CbGeAlD
Paroxetine—Hypersensitivity—Imiquimod—skin cancer	0.000287	0.000719	CcSEcCtD
Paroxetine—Headache—Vemurafenib—skin cancer	0.000286	0.000717	CcSEcCtD
Paroxetine—Malnutrition—Temozolomide—skin cancer	0.000286	0.000717	CcSEcCtD
Paroxetine—Erythema—Temozolomide—skin cancer	0.000286	0.000717	CcSEcCtD
Paroxetine—Breast disorder—Docetaxel—skin cancer	0.000285	0.000715	CcSEcCtD
Paroxetine—Discomfort—Bleomycin—skin cancer	0.000285	0.000715	CcSEcCtD
Paroxetine—Malaise—Dactinomycin—skin cancer	0.000285	0.000715	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000284	0.000713	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000284	0.000713	CcSEcCtD
Paroxetine—Cramp muscle—Docetaxel—skin cancer	0.000284	0.000713	CcSEcCtD
Paroxetine—Leukopenia—Dactinomycin—skin cancer	0.000283	0.00071	CcSEcCtD
Paroxetine—Nasopharyngitis—Docetaxel—skin cancer	0.000282	0.000708	CcSEcCtD
Paroxetine—Dysgeusia—Temozolomide—skin cancer	0.00028	0.000702	CcSEcCtD
Paroxetine—Asthenia—Imiquimod—skin cancer	0.000279	0.000701	CcSEcCtD
Paroxetine—Confusional state—Bleomycin—skin cancer	0.000279	0.000699	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000278	0.000698	CcSEcCtD
Paroxetine—Anaphylactic shock—Bleomycin—skin cancer	0.000277	0.000694	CcSEcCtD
Paroxetine—Oedema—Bleomycin—skin cancer	0.000277	0.000694	CcSEcCtD
Paroxetine—Back pain—Temozolomide—skin cancer	0.000277	0.000693	CcSEcCtD
Paroxetine—Pruritus—Imiquimod—skin cancer	0.000275	0.000691	CcSEcCtD
Paroxetine—Infection—Bleomycin—skin cancer	0.000275	0.000689	CcSEcCtD
Paroxetine—Dysphagia—Docetaxel—skin cancer	0.000273	0.000684	CcSEcCtD
Paroxetine—Nausea—Vemurafenib—skin cancer	0.000271	0.00068	CcSEcCtD
Paroxetine—Thrombocytopenia—Bleomycin—skin cancer	0.000271	0.000679	CcSEcCtD
Paroxetine—Arrhythmia—Fluorouracil—skin cancer	0.00027	0.000678	CcSEcCtD
Paroxetine—Vision blurred—Temozolomide—skin cancer	0.000269	0.000676	CcSEcCtD
Paroxetine—Myalgia—Dactinomycin—skin cancer	0.000269	0.000675	CcSEcCtD
Paroxetine—Tremor—Temozolomide—skin cancer	0.000268	0.000672	CcSEcCtD
Paroxetine—Alopecia—Fluorouracil—skin cancer	0.000267	0.000671	CcSEcCtD
Paroxetine—Diarrhoea—Imiquimod—skin cancer	0.000266	0.000668	CcSEcCtD
Paroxetine—Discomfort—Dactinomycin—skin cancer	0.000266	0.000667	CcSEcCtD
Paroxetine—Angina pectoris—Docetaxel—skin cancer	0.000266	0.000667	CcSEcCtD
Paroxetine—Ill-defined disorder—Temozolomide—skin cancer	0.000265	0.000665	CcSEcCtD
Paroxetine—Anaemia—Temozolomide—skin cancer	0.000264	0.000663	CcSEcCtD
Paroxetine—Erythema—Fluorouracil—skin cancer	0.000263	0.000661	CcSEcCtD
Paroxetine—Agitation—Temozolomide—skin cancer	0.000263	0.000659	CcSEcCtD
Paroxetine—Angioedema—Temozolomide—skin cancer	0.000261	0.000655	CcSEcCtD
Paroxetine—Pancytopenia—Docetaxel—skin cancer	0.000259	0.00065	CcSEcCtD
Paroxetine—Hypotension—Bleomycin—skin cancer	0.000258	0.000648	CcSEcCtD
Paroxetine—Oedema—Dactinomycin—skin cancer	0.000258	0.000647	CcSEcCtD
Paroxetine—Malaise—Temozolomide—skin cancer	0.000258	0.000647	CcSEcCtD
Paroxetine—Dizziness—Imiquimod—skin cancer	0.000257	0.000646	CcSEcCtD
Paroxetine—Vertigo—Temozolomide—skin cancer	0.000257	0.000644	CcSEcCtD
Paroxetine—Infection—Dactinomycin—skin cancer	0.000256	0.000643	CcSEcCtD
Paroxetine—Leukopenia—Temozolomide—skin cancer	0.000256	0.000642	CcSEcCtD
Paroxetine—Palpitations—Temozolomide—skin cancer	0.000253	0.000634	CcSEcCtD
Paroxetine—Thrombocytopenia—Dactinomycin—skin cancer	0.000253	0.000633	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000252	0.000632	CcSEcCtD
Paroxetine—Cough—Temozolomide—skin cancer	0.000249	0.000626	CcSEcCtD
Paroxetine—Paraesthesia—Bleomycin—skin cancer	0.000248	0.000623	CcSEcCtD
Paroxetine—Weight increased—Docetaxel—skin cancer	0.000248	0.000623	CcSEcCtD
Paroxetine—Vision blurred—Fluorouracil—skin cancer	0.000248	0.000623	CcSEcCtD
Paroxetine—Convulsion—Temozolomide—skin cancer	0.000248	0.000621	CcSEcCtD
Paroxetine—Vomiting—Imiquimod—skin cancer	0.000248	0.000621	CcSEcCtD
Paroxetine—Weight decreased—Docetaxel—skin cancer	0.000247	0.000619	CcSEcCtD
Paroxetine—Hypertension—Temozolomide—skin cancer	0.000247	0.000619	CcSEcCtD
Paroxetine—Dyspnoea—Bleomycin—skin cancer	0.000247	0.000618	CcSEcCtD
Paroxetine—Rash—Imiquimod—skin cancer	0.000246	0.000616	CcSEcCtD
Paroxetine—Dermatitis—Imiquimod—skin cancer	0.000245	0.000615	CcSEcCtD
Paroxetine—Pneumonia—Docetaxel—skin cancer	0.000245	0.000614	CcSEcCtD
Paroxetine—Headache—Imiquimod—skin cancer	0.000244	0.000612	CcSEcCtD
Paroxetine—Anaemia—Fluorouracil—skin cancer	0.000243	0.000611	CcSEcCtD
Paroxetine—Myalgia—Temozolomide—skin cancer	0.000243	0.00061	CcSEcCtD
Paroxetine—Arthralgia—Temozolomide—skin cancer	0.000243	0.00061	CcSEcCtD
Paroxetine—Anxiety—Temozolomide—skin cancer	0.000243	0.000608	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000242	0.000606	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000241	0.000605	CcSEcCtD
Paroxetine—Discomfort—Temozolomide—skin cancer	0.00024	0.000603	CcSEcCtD
Paroxetine—Decreased appetite—Bleomycin—skin cancer	0.00024	0.000603	CcSEcCtD
Paroxetine—Acute coronary syndrome—Docetaxel—skin cancer	0.00024	0.000601	CcSEcCtD
Paroxetine—Myocardial infarction—Docetaxel—skin cancer	0.000238	0.000598	CcSEcCtD
Paroxetine—Neuropathy peripheral—Docetaxel—skin cancer	0.000238	0.000598	CcSEcCtD
Paroxetine—Dry mouth—Temozolomide—skin cancer	0.000238	0.000597	CcSEcCtD
Paroxetine—Jaundice—Docetaxel—skin cancer	0.000237	0.000595	CcSEcCtD
Paroxetine—Stomatitis—Docetaxel—skin cancer	0.000237	0.000595	CcSEcCtD
Paroxetine—Pain—Bleomycin—skin cancer	0.000237	0.000593	CcSEcCtD
Paroxetine—Conjunctivitis—Docetaxel—skin cancer	0.000236	0.000593	CcSEcCtD
Paroxetine—Leukopenia—Fluorouracil—skin cancer	0.000236	0.000591	CcSEcCtD
Paroxetine—Confusional state—Temozolomide—skin cancer	0.000235	0.00059	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000235	0.000589	CcSEcCtD
Paroxetine—Oedema—Temozolomide—skin cancer	0.000233	0.000585	CcSEcCtD
Paroxetine—Anaphylactic shock—Temozolomide—skin cancer	0.000233	0.000585	CcSEcCtD
Paroxetine—Infection—Temozolomide—skin cancer	0.000232	0.000581	CcSEcCtD
Paroxetine—Nausea—Imiquimod—skin cancer	0.000231	0.00058	CcSEcCtD
Paroxetine—Hepatobiliary disease—Docetaxel—skin cancer	0.00023	0.000577	CcSEcCtD
Paroxetine—Epistaxis—Docetaxel—skin cancer	0.000229	0.000575	CcSEcCtD
Paroxetine—Nervous system disorder—Temozolomide—skin cancer	0.000229	0.000574	CcSEcCtD
Paroxetine—Thrombocytopenia—Temozolomide—skin cancer	0.000228	0.000573	CcSEcCtD
Paroxetine—Convulsion—Fluorouracil—skin cancer	0.000228	0.000572	CcSEcCtD
Paroxetine—Feeling abnormal—Bleomycin—skin cancer	0.000228	0.000572	CcSEcCtD
Paroxetine—Agranulocytosis—Docetaxel—skin cancer	0.000227	0.000569	CcSEcCtD
Paroxetine—Skin disorder—Temozolomide—skin cancer	0.000227	0.000568	CcSEcCtD
Paroxetine—Hyperhidrosis—Temozolomide—skin cancer	0.000226	0.000566	CcSEcCtD
Paroxetine—Chest pain—Fluorouracil—skin cancer	0.000224	0.000562	CcSEcCtD
Paroxetine—Myalgia—Fluorouracil—skin cancer	0.000224	0.000562	CcSEcCtD
Paroxetine—Decreased appetite—Dactinomycin—skin cancer	0.000224	0.000562	CcSEcCtD
Paroxetine—Fatigue—Dactinomycin—skin cancer	0.000222	0.000558	CcSEcCtD
Paroxetine—Discomfort—Fluorouracil—skin cancer	0.000222	0.000556	CcSEcCtD
Paroxetine—Pain—Dactinomycin—skin cancer	0.000221	0.000553	CcSEcCtD
Paroxetine—Urticaria—Bleomycin—skin cancer	0.00022	0.000551	CcSEcCtD
Paroxetine—Haemoglobin—Docetaxel—skin cancer	0.00022	0.00055	CcSEcCtD
Paroxetine—Rhinitis—Docetaxel—skin cancer	0.000219	0.000549	CcSEcCtD
Paroxetine—Body temperature increased—Bleomycin—skin cancer	0.000219	0.000548	CcSEcCtD
Paroxetine—Haemorrhage—Docetaxel—skin cancer	0.000218	0.000548	CcSEcCtD
Paroxetine—Hepatitis—Docetaxel—skin cancer	0.000218	0.000548	CcSEcCtD
Paroxetine—Hypoaesthesia—Docetaxel—skin cancer	0.000217	0.000545	CcSEcCtD
Paroxetine—Confusional state—Fluorouracil—skin cancer	0.000217	0.000544	CcSEcCtD
Paroxetine—Pharyngitis—Docetaxel—skin cancer	0.000217	0.000544	CcSEcCtD
Paroxetine—Oedema peripheral—Docetaxel—skin cancer	0.000215	0.00054	CcSEcCtD
Paroxetine—Oedema—Fluorouracil—skin cancer	0.000215	0.000539	CcSEcCtD
Paroxetine—Anaphylactic shock—Fluorouracil—skin cancer	0.000215	0.000539	CcSEcCtD
Paroxetine—Connective tissue disorder—Docetaxel—skin cancer	0.000215	0.000538	CcSEcCtD
Paroxetine—Infection—Fluorouracil—skin cancer	0.000214	0.000536	CcSEcCtD
Paroxetine—Feeling abnormal—Dactinomycin—skin cancer	0.000213	0.000533	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000213	0.000533	CcSEcCtD
Paroxetine—Insomnia—Temozolomide—skin cancer	0.000211	0.000529	CcSEcCtD
Paroxetine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000211	0.000529	CcSEcCtD
Paroxetine—Nervous system disorder—Fluorouracil—skin cancer	0.000211	0.000529	CcSEcCtD
Paroxetine—Thrombocytopenia—Fluorouracil—skin cancer	0.00021	0.000528	CcSEcCtD
Paroxetine—Visual impairment—Docetaxel—skin cancer	0.00021	0.000528	CcSEcCtD
Paroxetine—Tachycardia—Fluorouracil—skin cancer	0.00021	0.000526	CcSEcCtD
Paroxetine—Paraesthesia—Temozolomide—skin cancer	0.00021	0.000525	CcSEcCtD
Paroxetine—Dyspnoea—Temozolomide—skin cancer	0.000208	0.000522	CcSEcCtD
Paroxetine—Somnolence—Temozolomide—skin cancer	0.000207	0.00052	CcSEcCtD
Paroxetine—Erythema multiforme—Docetaxel—skin cancer	0.000207	0.000518	CcSEcCtD
Paroxetine—Dyspepsia—Temozolomide—skin cancer	0.000205	0.000515	CcSEcCtD
Paroxetine—Eye disorder—Docetaxel—skin cancer	0.000204	0.000512	CcSEcCtD
Paroxetine—Abdominal pain—Dactinomycin—skin cancer	0.000204	0.000511	CcSEcCtD
Paroxetine—Body temperature increased—Dactinomycin—skin cancer	0.000204	0.000511	CcSEcCtD
Paroxetine—Hypersensitivity—Bleomycin—skin cancer	0.000204	0.000511	CcSEcCtD
Paroxetine—Decreased appetite—Temozolomide—skin cancer	0.000203	0.000509	CcSEcCtD
Paroxetine—Cardiac disorder—Docetaxel—skin cancer	0.000203	0.000508	CcSEcCtD
Paroxetine—Flushing—Docetaxel—skin cancer	0.000203	0.000508	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000201	0.000505	CcSEcCtD
Paroxetine—ABCB1—lymph node—skin cancer	0.000201	0.0026	CbGeAlD
Paroxetine—Fatigue—Temozolomide—skin cancer	0.000201	0.000504	CcSEcCtD
Paroxetine—Hypotension—Fluorouracil—skin cancer	0.000201	0.000504	CcSEcCtD
Paroxetine—Constipation—Temozolomide—skin cancer	0.0002	0.0005	CcSEcCtD
Paroxetine—Pain—Temozolomide—skin cancer	0.0002	0.0005	CcSEcCtD
Paroxetine—Asthenia—Bleomycin—skin cancer	0.000198	0.000498	CcSEcCtD
Paroxetine—Angiopathy—Docetaxel—skin cancer	0.000198	0.000497	CcSEcCtD
Paroxetine—Immune system disorder—Docetaxel—skin cancer	0.000197	0.000495	CcSEcCtD
Paroxetine—Mediastinal disorder—Docetaxel—skin cancer	0.000197	0.000494	CcSEcCtD
Paroxetine—Chills—Docetaxel—skin cancer	0.000196	0.000491	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000196	0.000491	CcSEcCtD
Paroxetine—Pruritus—Bleomycin—skin cancer	0.000196	0.000491	CcSEcCtD
Paroxetine—Arrhythmia—Docetaxel—skin cancer	0.000195	0.000489	CcSEcCtD
Paroxetine—Insomnia—Fluorouracil—skin cancer	0.000194	0.000488	CcSEcCtD
Paroxetine—Paraesthesia—Fluorouracil—skin cancer	0.000193	0.000484	CcSEcCtD
Paroxetine—Alopecia—Docetaxel—skin cancer	0.000193	0.000484	CcSEcCtD
Paroxetine—Feeling abnormal—Temozolomide—skin cancer	0.000192	0.000482	CcSEcCtD
Paroxetine—Dyspnoea—Fluorouracil—skin cancer	0.000192	0.000481	CcSEcCtD
Paroxetine—Mental disorder—Docetaxel—skin cancer	0.000191	0.00048	CcSEcCtD
Paroxetine—Somnolence—Fluorouracil—skin cancer	0.000191	0.000479	CcSEcCtD
Paroxetine—Gastrointestinal pain—Temozolomide—skin cancer	0.000191	0.000478	CcSEcCtD
Paroxetine—Erythema—Docetaxel—skin cancer	0.00019	0.000477	CcSEcCtD
Paroxetine—Malnutrition—Docetaxel—skin cancer	0.00019	0.000477	CcSEcCtD
Paroxetine—Hypersensitivity—Dactinomycin—skin cancer	0.00019	0.000477	CcSEcCtD
Paroxetine—Dyspepsia—Fluorouracil—skin cancer	0.000189	0.000475	CcSEcCtD
Paroxetine—Decreased appetite—Fluorouracil—skin cancer	0.000187	0.000469	CcSEcCtD
Paroxetine—Dysgeusia—Docetaxel—skin cancer	0.000186	0.000467	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000186	0.000465	CcSEcCtD
Paroxetine—Urticaria—Temozolomide—skin cancer	0.000185	0.000465	CcSEcCtD
Paroxetine—Asthenia—Dactinomycin—skin cancer	0.000185	0.000464	CcSEcCtD
Paroxetine—Abdominal pain—Temozolomide—skin cancer	0.000184	0.000463	CcSEcCtD
Paroxetine—Body temperature increased—Temozolomide—skin cancer	0.000184	0.000463	CcSEcCtD
Paroxetine—Back pain—Docetaxel—skin cancer	0.000184	0.000461	CcSEcCtD
Paroxetine—Pain—Fluorouracil—skin cancer	0.000184	0.000461	CcSEcCtD
Paroxetine—Muscle spasms—Docetaxel—skin cancer	0.000183	0.000458	CcSEcCtD
Paroxetine—Feeling abnormal—Fluorouracil—skin cancer	0.000177	0.000444	CcSEcCtD
Paroxetine—Diarrhoea—Dactinomycin—skin cancer	0.000177	0.000443	CcSEcCtD
Paroxetine—Vomiting—Bleomycin—skin cancer	0.000176	0.000441	CcSEcCtD
Paroxetine—Anaemia—Docetaxel—skin cancer	0.000176	0.000441	CcSEcCtD
Paroxetine—Rash—Bleomycin—skin cancer	0.000174	0.000437	CcSEcCtD
Paroxetine—Dermatitis—Bleomycin—skin cancer	0.000174	0.000437	CcSEcCtD
Paroxetine—Hypersensitivity—Temozolomide—skin cancer	0.000172	0.000431	CcSEcCtD
Paroxetine—Urticaria—Fluorouracil—skin cancer	0.000171	0.000428	CcSEcCtD
Paroxetine—Syncope—Docetaxel—skin cancer	0.000171	0.000428	CcSEcCtD
Paroxetine—Leukopenia—Docetaxel—skin cancer	0.00017	0.000427	CcSEcCtD
Paroxetine—Body temperature increased—Fluorouracil—skin cancer	0.00017	0.000426	CcSEcCtD
Paroxetine—Palpitations—Docetaxel—skin cancer	0.000168	0.000421	CcSEcCtD
Paroxetine—Asthenia—Temozolomide—skin cancer	0.000167	0.00042	CcSEcCtD
Paroxetine—Loss of consciousness—Docetaxel—skin cancer	0.000167	0.000419	CcSEcCtD
Paroxetine—Cough—Docetaxel—skin cancer	0.000166	0.000416	CcSEcCtD
Paroxetine—Pruritus—Temozolomide—skin cancer	0.000165	0.000414	CcSEcCtD
Paroxetine—Convulsion—Docetaxel—skin cancer	0.000165	0.000413	CcSEcCtD
Paroxetine—Nausea—Bleomycin—skin cancer	0.000164	0.000412	CcSEcCtD
Paroxetine—Hypertension—Docetaxel—skin cancer	0.000164	0.000412	CcSEcCtD
Paroxetine—Vomiting—Dactinomycin—skin cancer	0.000164	0.000411	CcSEcCtD
Paroxetine—Rash—Dactinomycin—skin cancer	0.000163	0.000408	CcSEcCtD
Paroxetine—Arthralgia—Docetaxel—skin cancer	0.000162	0.000406	CcSEcCtD
Paroxetine—Myalgia—Docetaxel—skin cancer	0.000162	0.000406	CcSEcCtD
Paroxetine—Chest pain—Docetaxel—skin cancer	0.000162	0.000406	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000161	0.000403	CcSEcCtD
Paroxetine—Diarrhoea—Temozolomide—skin cancer	0.00016	0.0004	CcSEcCtD
Paroxetine—Hypersensitivity—Fluorouracil—skin cancer	0.000158	0.000397	CcSEcCtD
Paroxetine—Dry mouth—Docetaxel—skin cancer	0.000158	0.000397	CcSEcCtD
Paroxetine—Confusional state—Docetaxel—skin cancer	0.000156	0.000392	CcSEcCtD
Paroxetine—Oedema—Docetaxel—skin cancer	0.000155	0.000389	CcSEcCtD
Paroxetine—Anaphylactic shock—Docetaxel—skin cancer	0.000155	0.000389	CcSEcCtD
Paroxetine—Dizziness—Temozolomide—skin cancer	0.000154	0.000387	CcSEcCtD
Paroxetine—Infection—Docetaxel—skin cancer	0.000154	0.000387	CcSEcCtD
Paroxetine—Nausea—Dactinomycin—skin cancer	0.000153	0.000384	CcSEcCtD
Paroxetine—Shock—Docetaxel—skin cancer	0.000153	0.000383	CcSEcCtD
Paroxetine—Nervous system disorder—Docetaxel—skin cancer	0.000152	0.000382	CcSEcCtD
Paroxetine—Pruritus—Fluorouracil—skin cancer	0.000152	0.000381	CcSEcCtD
Paroxetine—Thrombocytopenia—Docetaxel—skin cancer	0.000152	0.000381	CcSEcCtD
Paroxetine—Tachycardia—Docetaxel—skin cancer	0.000151	0.00038	CcSEcCtD
Paroxetine—Skin disorder—Docetaxel—skin cancer	0.000151	0.000378	CcSEcCtD
Paroxetine—Vomiting—Temozolomide—skin cancer	0.000148	0.000372	CcSEcCtD
Paroxetine—Rash—Temozolomide—skin cancer	0.000147	0.000369	CcSEcCtD
Paroxetine—Diarrhoea—Fluorouracil—skin cancer	0.000147	0.000369	CcSEcCtD
Paroxetine—Dermatitis—Temozolomide—skin cancer	0.000147	0.000369	CcSEcCtD
Paroxetine—Headache—Temozolomide—skin cancer	0.000146	0.000367	CcSEcCtD
Paroxetine—Hypotension—Docetaxel—skin cancer	0.000145	0.000364	CcSEcCtD
Paroxetine—Dizziness—Fluorouracil—skin cancer	0.000142	0.000356	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000141	0.000355	CcSEcCtD
Paroxetine—Insomnia—Docetaxel—skin cancer	0.00014	0.000352	CcSEcCtD
Paroxetine—Paraesthesia—Docetaxel—skin cancer	0.000139	0.000349	CcSEcCtD
Paroxetine—Nausea—Temozolomide—skin cancer	0.000139	0.000348	CcSEcCtD
Paroxetine—Dyspnoea—Docetaxel—skin cancer	0.000138	0.000347	CcSEcCtD
Paroxetine—Somnolence—Docetaxel—skin cancer	0.000138	0.000346	CcSEcCtD
Paroxetine—Vomiting—Fluorouracil—skin cancer	0.000137	0.000343	CcSEcCtD
Paroxetine—Dyspepsia—Docetaxel—skin cancer	0.000137	0.000343	CcSEcCtD
Paroxetine—Rash—Fluorouracil—skin cancer	0.000136	0.00034	CcSEcCtD
Paroxetine—Dermatitis—Fluorouracil—skin cancer	0.000135	0.00034	CcSEcCtD
Paroxetine—Decreased appetite—Docetaxel—skin cancer	0.000135	0.000338	CcSEcCtD
Paroxetine—Headache—Fluorouracil—skin cancer	0.000135	0.000338	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000134	0.000336	CcSEcCtD
Paroxetine—Fatigue—Docetaxel—skin cancer	0.000134	0.000335	CcSEcCtD
Paroxetine—Pain—Docetaxel—skin cancer	0.000133	0.000333	CcSEcCtD
Paroxetine—Constipation—Docetaxel—skin cancer	0.000133	0.000333	CcSEcCtD
Paroxetine—Feeling abnormal—Docetaxel—skin cancer	0.000128	0.000321	CcSEcCtD
Paroxetine—Nausea—Fluorouracil—skin cancer	0.000128	0.00032	CcSEcCtD
Paroxetine—Gastrointestinal pain—Docetaxel—skin cancer	0.000127	0.000318	CcSEcCtD
Paroxetine—Body temperature increased—Docetaxel—skin cancer	0.000123	0.000308	CcSEcCtD
Paroxetine—Abdominal pain—Docetaxel—skin cancer	0.000123	0.000308	CcSEcCtD
Paroxetine—Hypersensitivity—Docetaxel—skin cancer	0.000114	0.000287	CcSEcCtD
Paroxetine—Asthenia—Docetaxel—skin cancer	0.000111	0.000279	CcSEcCtD
Paroxetine—Pruritus—Docetaxel—skin cancer	0.00011	0.000275	CcSEcCtD
Paroxetine—Diarrhoea—Docetaxel—skin cancer	0.000106	0.000266	CcSEcCtD
Paroxetine—Dizziness—Docetaxel—skin cancer	0.000103	0.000257	CcSEcCtD
Paroxetine—Vomiting—Docetaxel—skin cancer	9.87e-05	0.000247	CcSEcCtD
Paroxetine—Rash—Docetaxel—skin cancer	9.78e-05	0.000245	CcSEcCtD
Paroxetine—Dermatitis—Docetaxel—skin cancer	9.77e-05	0.000245	CcSEcCtD
Paroxetine—Headache—Docetaxel—skin cancer	9.72e-05	0.000244	CcSEcCtD
Paroxetine—Nausea—Docetaxel—skin cancer	9.22e-05	0.000231	CcSEcCtD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.83e-05	0.00179	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—FOXO4—skin cancer	1.78e-05	0.00174	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—MC1R—skin cancer	1.78e-05	0.00174	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—MC1R—skin cancer	1.77e-05	0.00173	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—MC1R—skin cancer	1.76e-05	0.00172	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—BRAF—skin cancer	1.76e-05	0.00172	CbGpPWpGaD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.76e-05	0.00172	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—MC1R—skin cancer	1.75e-05	0.00171	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—PTGER4—skin cancer	1.73e-05	0.00169	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—SHH—skin cancer	1.7e-05	0.00166	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—PTGER4—skin cancer	1.65e-05	0.00161	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—SHH—skin cancer	1.63e-05	0.00159	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—skin cancer	1.62e-05	0.00158	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MC1R—skin cancer	1.61e-05	0.00158	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PTCH1—skin cancer	1.61e-05	0.00157	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—SMO—skin cancer	1.61e-05	0.00157	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MC1R—skin cancer	1.61e-05	0.00157	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MC1R—skin cancer	1.6e-05	0.00156	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MC1R—skin cancer	1.59e-05	0.00155	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PTGER4—skin cancer	1.57e-05	0.00153	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PTCH1—skin cancer	1.54e-05	0.00151	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—SMO—skin cancer	1.54e-05	0.00151	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.52e-05	0.00149	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PTGER4—skin cancer	1.5e-05	0.00147	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GLI2—skin cancer	1.48e-05	0.00144	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PLIN2—skin cancer	1.47e-05	0.00144	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—TP53—skin cancer	1.45e-05	0.00141	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—NRAS—skin cancer	1.44e-05	0.0014	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—NRAS—skin cancer	1.43e-05	0.0014	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—NRAS—skin cancer	1.42e-05	0.00139	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GLI2—skin cancer	1.41e-05	0.00138	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MC1R—skin cancer	1.41e-05	0.00138	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GLI1—skin cancer	1.39e-05	0.00136	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MC1R—skin cancer	1.35e-05	0.00132	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.34e-05	0.00131	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GLI1—skin cancer	1.33e-05	0.0013	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—IL6—skin cancer	1.32e-05	0.00129	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTCH2—skin cancer	1.32e-05	0.00129	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SUFU—skin cancer	1.31e-05	0.00128	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTCH2—skin cancer	1.31e-05	0.00128	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.31e-05	0.00128	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTCH2—skin cancer	1.31e-05	0.00128	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTCH2—skin cancer	1.3e-05	0.00127	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PLIN2—skin cancer	1.27e-05	0.00124	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SUFU—skin cancer	1.26e-05	0.00123	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.24e-05	0.00121	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.23e-05	0.0012	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.22e-05	0.00119	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TERT—skin cancer	1.19e-05	0.00116	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CSPG4—skin cancer	1.19e-05	0.00116	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PTGER4—skin cancer	1.17e-05	0.00114	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PTGER4—skin cancer	1.16e-05	0.00114	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PTGER4—skin cancer	1.16e-05	0.00113	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—SHH—skin cancer	1.15e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PTGER4—skin cancer	1.15e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—SHH—skin cancer	1.14e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—SHH—skin cancer	1.14e-05	0.00111	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—SHH—skin cancer	1.13e-05	0.0011	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.11e-05	0.00109	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PTCH1—skin cancer	1.09e-05	0.00107	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—SMO—skin cancer	1.09e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PTCH1—skin cancer	1.09e-05	0.00106	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—SMO—skin cancer	1.09e-05	0.00106	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PTCH1—skin cancer	1.08e-05	0.00106	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—SMO—skin cancer	1.08e-05	0.00106	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.08e-05	0.00105	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.07e-05	0.00105	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PLIN2—skin cancer	1.07e-05	0.00105	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PTCH1—skin cancer	1.07e-05	0.00105	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—SMO—skin cancer	1.07e-05	0.00105	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.07e-05	0.00104	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.07e-05	0.00104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PTGER4—skin cancer	1.06e-05	0.00104	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	1.06e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PTGER4—skin cancer	1.06e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PTGER4—skin cancer	1.05e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PTGER4—skin cancer	1.04e-05	0.00102	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CSPG4—skin cancer	1.02e-05	0.000997	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SHH—skin cancer	1e-05	0.00098	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—NRAS—skin cancer	1e-05	0.000979	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GLI2—skin cancer	1e-05	0.000977	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RASA1—skin cancer	9.96e-06	0.000974	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GLI2—skin cancer	9.95e-06	0.000972	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GLI2—skin cancer	9.92e-06	0.000969	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GLI2—skin cancer	9.82e-06	0.00096	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—IL6—skin cancer	9.75e-06	0.000953	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SHH—skin cancer	9.6e-06	0.000938	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	9.58e-06	0.000936	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—IL6—skin cancer	9.58e-06	0.000936	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RASA1—skin cancer	9.54e-06	0.000932	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MC1R—skin cancer	9.54e-06	0.000932	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTCH1—skin cancer	9.51e-06	0.000929	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SMO—skin cancer	9.51e-06	0.000929	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MC1R—skin cancer	9.49e-06	0.000927	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MC1R—skin cancer	9.46e-06	0.000924	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—BRAF—skin cancer	9.42e-06	0.00092	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GLI1—skin cancer	9.4e-06	0.000919	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MC1R—skin cancer	9.37e-06	0.000915	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GLI1—skin cancer	9.35e-06	0.000914	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PLIN2—skin cancer	9.33e-06	0.000912	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GLI1—skin cancer	9.32e-06	0.000911	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	9.27e-06	0.000906	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTGER4—skin cancer	9.25e-06	0.000904	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GLI1—skin cancer	9.23e-06	0.000902	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	9.23e-06	0.000901	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	9.2e-06	0.000899	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SMO—skin cancer	9.1e-06	0.00089	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTCH1—skin cancer	9.1e-06	0.00089	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SUFU—skin cancer	8.91e-06	0.000871	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SUFU—skin cancer	8.87e-06	0.000866	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTGER4—skin cancer	8.86e-06	0.000866	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SUFU—skin cancer	8.84e-06	0.000864	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PLIN2—skin cancer	8.8e-06	0.00086	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SUFU—skin cancer	8.75e-06	0.000855	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PLIN2—skin cancer	8.72e-06	0.000852	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—skin cancer	8.65e-06	0.000846	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CSPG4—skin cancer	8.64e-06	0.000844	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—KRAS—skin cancer	8.62e-06	0.000843	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—FOXO4—skin cancer	8.17e-06	0.000799	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—HRAS—skin cancer	8.1e-06	0.000792	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ENO2—skin cancer	8.06e-06	0.000788	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—IL6—skin cancer	7.92e-06	0.000774	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.88e-06	0.00077	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.84e-06	0.000766	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—FOXO4—skin cancer	7.83e-06	0.000765	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.82e-06	0.000764	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	7.55e-06	0.000737	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CSPG4—skin cancer	7.52e-06	0.000735	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	7.5e-06	0.000733	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	7.48e-06	0.000731	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HRAS—skin cancer	7.33e-06	0.000716	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CSPG4—skin cancer	7.09e-06	0.000693	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CSPG4—skin cancer	7.03e-06	0.000687	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—skin cancer	7.01e-06	0.000685	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ENO2—skin cancer	6.93e-06	0.000678	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SHH—skin cancer	6.8e-06	0.000664	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SHH—skin cancer	6.76e-06	0.000661	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RASA1—skin cancer	6.75e-06	0.00066	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SHH—skin cancer	6.74e-06	0.000659	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RASA1—skin cancer	6.72e-06	0.000657	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RASA1—skin cancer	6.7e-06	0.000654	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SHH—skin cancer	6.67e-06	0.000652	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RASA1—skin cancer	6.63e-06	0.000648	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SMO—skin cancer	6.44e-06	0.00063	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTCH1—skin cancer	6.44e-06	0.00063	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.41e-06	0.000627	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTCH1—skin cancer	6.41e-06	0.000626	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SMO—skin cancer	6.41e-06	0.000626	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SMO—skin cancer	6.39e-06	0.000624	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTCH1—skin cancer	6.39e-06	0.000624	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SMO—skin cancer	6.33e-06	0.000618	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTCH1—skin cancer	6.33e-06	0.000618	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTGER4—skin cancer	6.27e-06	0.000613	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTGER4—skin cancer	6.24e-06	0.00061	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTGER4—skin cancer	6.22e-06	0.000608	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTGER4—skin cancer	6.16e-06	0.000602	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NRAS—skin cancer	5.92e-06	0.000578	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ENO2—skin cancer	5.87e-06	0.000574	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.7e-06	0.000557	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FOXO4—skin cancer	5.54e-06	0.000542	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FOXO4—skin cancer	5.51e-06	0.000539	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FOXO4—skin cancer	5.49e-06	0.000537	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TERT—skin cancer	5.46e-06	0.000534	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FOXO4—skin cancer	5.44e-06	0.000532	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TERT—skin cancer	5.23e-06	0.000511	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ENO2—skin cancer	5.11e-06	0.0005	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—KRAS—skin cancer	5.09e-06	0.000498	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ENO2—skin cancer	4.82e-06	0.000471	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ENO2—skin cancer	4.78e-06	0.000467	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ERCC2—skin cancer	4.68e-06	0.000458	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—NRAS—skin cancer	4.6e-06	0.00045	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.59e-06	0.000449	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—skin cancer	4.53e-06	0.000442	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—NRAS—skin cancer	4.41e-06	0.00043	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—skin cancer	4.33e-06	0.000423	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—BRAF—skin cancer	4.32e-06	0.000423	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—skin cancer	4.14e-06	0.000405	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—BRAF—skin cancer	4.14e-06	0.000405	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ERCC2—skin cancer	4.03e-06	0.000394	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—KRAS—skin cancer	3.96e-06	0.000387	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—KRAS—skin cancer	3.79e-06	0.00037	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.74e-06	0.000365	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TERT—skin cancer	3.7e-06	0.000362	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TERT—skin cancer	3.68e-06	0.00036	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TERT—skin cancer	3.67e-06	0.000359	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TERT—skin cancer	3.63e-06	0.000355	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ERCC2—skin cancer	3.41e-06	0.000333	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—skin cancer	3.37e-06	0.000329	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—skin cancer	3.22e-06	0.000315	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—skin cancer	3.22e-06	0.000315	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—NRAS—skin cancer	3.12e-06	0.000305	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—NRAS—skin cancer	3.1e-06	0.000303	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—NRAS—skin cancer	3.09e-06	0.000302	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—skin cancer	3.08e-06	0.000301	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—NRAS—skin cancer	3.06e-06	0.000299	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ERCC2—skin cancer	2.97e-06	0.00029	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—skin cancer	2.93e-06	0.000286	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—skin cancer	2.92e-06	0.000285	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—skin cancer	2.91e-06	0.000284	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—skin cancer	2.88e-06	0.000281	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—skin cancer	2.81e-06	0.000274	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ERCC2—skin cancer	2.8e-06	0.000274	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ERCC2—skin cancer	2.78e-06	0.000271	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—skin cancer	2.72e-06	0.000266	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—skin cancer	2.68e-06	0.000262	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—skin cancer	2.67e-06	0.000261	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—skin cancer	2.66e-06	0.00026	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—skin cancer	2.64e-06	0.000258	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—skin cancer	2.6e-06	0.000254	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—skin cancer	2.42e-06	0.000236	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—skin cancer	2.34e-06	0.000229	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—skin cancer	2.28e-06	0.000223	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—skin cancer	2.27e-06	0.000222	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—skin cancer	2.26e-06	0.000221	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—skin cancer	2.24e-06	0.000219	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—skin cancer	2.24e-06	0.000219	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—skin cancer	2.18e-06	0.000213	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—skin cancer	2.17e-06	0.000212	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—skin cancer	2.16e-06	0.000212	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—skin cancer	2.14e-06	0.000209	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—skin cancer	2.08e-06	0.000203	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—skin cancer	2.04e-06	0.0002	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—skin cancer	1.99e-06	0.000195	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—skin cancer	1.99e-06	0.000194	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—skin cancer	1.9e-06	0.000186	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—skin cancer	1.9e-06	0.000186	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—skin cancer	1.84e-06	0.00018	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—skin cancer	1.83e-06	0.000179	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—skin cancer	1.83e-06	0.000178	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—skin cancer	1.82e-06	0.000178	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—skin cancer	1.81e-06	0.000177	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—skin cancer	1.78e-06	0.000174	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—skin cancer	1.68e-06	0.000164	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—skin cancer	1.66e-06	0.000163	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—skin cancer	1.59e-06	0.000155	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—skin cancer	1.58e-06	0.000154	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—skin cancer	1.57e-06	0.000154	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—skin cancer	1.56e-06	0.000152	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—skin cancer	1.41e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—skin cancer	1.4e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—skin cancer	1.4e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—skin cancer	1.38e-06	0.000135	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—skin cancer	1.35e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—skin cancer	1.34e-06	0.000131	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—skin cancer	1.34e-06	0.000131	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—skin cancer	1.32e-06	0.000129	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—skin cancer	1.29e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—skin cancer	1.28e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—skin cancer	1.28e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—skin cancer	1.27e-06	0.000124	CbGpPWpGaD
